Organ-at-Risk Dose Constraints for Pediatric Neuroblastoma (21.6 Gy/12 Fractions)
For pediatric neuroblastoma receiving 21.6 Gy in 12 fractions (1.8 Gy per fraction), organ-at-risk constraints should prioritize kidney and liver sparing, though evidence demonstrates that exceeding traditional constraints does not necessarily result in clinically significant toxicity.
Key Dose Constraints
Kidneys
- Contralateral kidney: Mean dose <12 Gy, V12 <50% 1
- Ipsilateral kidney (if unresected): Mean dose <14.4 Gy 1
- Critical finding: Even when these constraints are not met, clinically significant renal toxicity is rare. In a series of 30 patients, only 2 of 3 patients who exceeded ipsilateral kidney constraints developed radiographic hypoplasia, but all maintained normal laboratory kidney function 1
Liver
- Mean dose: <20-25 Gy 1
- V20: <30-40% of liver volume
- Important caveat: No patients in the retrospective analysis developed RT-related late hepatic complications, even when DVH constraints were not achieved 1
Heart (for thoracic/supradiaphragmatic tumors)
- Mean dose: <15 Gy 2
- V20: <30%
- Proton therapy can reduce heart dose from 16 Gy to 6.6 Gy compared to 3D-CRT 2
Lungs (for thoracic tumors)
- Mean lung dose: <13-15 Gy 2
- V20: <25-30%
Spleen and Bowel (for abdominal tumors)
- Minimize dose where feasible, though specific constraints are not well-established
- Proton therapy provides statistically significant sparing compared to photon therapy 2
Vertebral Bodies
- Adjacent vertebrae: Dose homogeneity should be maintained, though specific constraints vary
- Non-adjacent vertebrae: Sparing remains challenging with both photon and proton techniques 2
Treatment Planning Considerations
The prescribed dose of 21.6 Gy in 12 fractions (1.8 Gy/fraction) is the standard for neuroblastoma based on COG protocols 3. This fractionation scheme allows for:
- Adequate tumor control while minimizing late effects
- Compatibility with both photon (VMAT) and proton therapy techniques
- Delivery to the preoperative disease volume as per HR-NBL2/SIOPEN protocol 2
Technique Selection
Proton therapy should be strongly considered when available, as it provides:
- Statistically significant dose reduction to all major organs at risk 2
- Particularly beneficial for bilateral disease or large tumor volumes
- Reduced integral dose to developing tissues in pediatric patients 4
When proton therapy is unavailable, VMAT is preferred over 3D-CRT for improved organ sparing 2, 5.
Critical Clinical Insight
The most important finding from outcome data is that current DVH constraints are highly conservative 1. The risk of clinically significant late toxicity to kidney and liver is minimal even when planning constraints are not achieved. This suggests that:
- Tumor coverage should not be compromised to meet arbitrary OAR constraints
- Individual patient factors (age, baseline organ function, tumor location) matter more than strict adherence to dose limits
- Long-term functional outcomes are generally favorable despite constraint violations
Imaging Dose Contribution
While planning CT and repeated CBCT contribute 3-7 mGy per organ per acquisition, the cumulative imaging dose remains <0.5 Gy (<1% of therapeutic dose) 5. This is biologically relevant but should not drive major planning decisions.
Practical Algorithm
- Prioritize tumor coverage to the full preoperative volume at 21.6 Gy/12 fractions
- Assess proton therapy availability - use if accessible for any thoracic or abdominal neuroblastoma
- If photon therapy required: Use VMAT with the following hierarchy:
- Contralateral kidney mean dose <12 Gy (highest priority)
- Liver mean dose <25 Gy
- Heart mean dose <15 Gy (for thoracic tumors)
- Lung V20 <30% (for thoracic tumors)
- Do not compromise target coverage if OAR constraints cannot be met - toxicity risk remains low 1
- Document any constraint violations and plan for appropriate organ-specific surveillance